Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients

Introduction: Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) that is known to have unique immunomodulatory effects. In particular, dasatinib intake typically causes lymphocytosis, which has been linked to better clinical response. Since the underly...

Descripción completa

Detalles Bibliográficos
Autores principales: Colom-Fernández, Beatriz, Kreutzman, Anna, Marcos-Jiménez, Ana, García-Gutiérrez, Valentín, Cuesta-Mateos, Carlos, Portero-Sainz, Itxaso, Pérez-García, Yaiza, Casado, Luis Felipe, Sánchez-Guijo, Fermín, Martínez-López, Joaquín, Ayala, Rosa M., Boqué, Concha, Xicoy, Blanca, Montero, Isabel, Soto, César, Paz, Raquel, Silva, Gabriela, Vega-Piris, Lorena, Steegmann, Juan Luis, Muñoz-Calleja, Cecilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886582/
https://www.ncbi.nlm.nih.gov/pubmed/31824308
http://dx.doi.org/10.3389/fphar.2019.01340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886582/
https://www.ncbi.nlm.nih.gov/pubmed/31824308
http://dx.doi.org/10.3389/fphar.2019.01340

Ejemplares similares